A Supreme Court ruling that plaintiffs do not need to prove that a company’s misrepresentations were material in order to obtain class certification will make it easier for plaintiffs to pursue such cases against pharmaceutical companies.
In its Feb. 27 decision in Amgen Inc. v
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?